{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:16:46Z","timestamp":1777349806658,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"crossref","award":["2015020547"],"award-info":[{"award-number":["2015020547"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2015M581375"],"award-info":[{"award-number":["2015M581375"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81371395"],"award-info":[{"award-number":["81371395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0251-0","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T12:46:02Z","timestamp":1538397962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The critical interaction between valproate sodium and warfarin: case report and review"],"prefix":"10.1186","volume":"19","author":[{"given":"Chenguang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-7877","authenticated-orcid":false,"given":"Yi","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"251_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.yebeh.2017.05.022","volume":"73","author":"E Bruun","year":"2017","unstructured":"Bruun E, Virta LJ, Kalviainen R, Keranen T. Co-morbidity and clinically significant interactions between antiepileptic drugs and other drugs in elderly patients with newly diagnosed epilepsy. Epilepsy Behav. 2017;73:71\u20136.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"251_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347\u201356.","journal-title":"Lancet Neurol"},{"issue":"2","key":"251_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00004714-199504000-00010","volume":"15","author":"SK Guthrie","year":"1995","unstructured":"Guthrie SK, Stoysich AM, Bader G, Hilleman DE. Hypothesized interaction between valproic acid and warfarin. J Clin Psychopharmacol. 1995;15(2):138\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"251_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/00002512-200320020-00005","volume":"20","author":"LJ Stephen","year":"2003","unstructured":"Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging. 2003;20(2):141\u201352.","journal-title":"Drugs Aging"},{"issue":"1","key":"251_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12028-011-9544-5","volume":"15","author":"HW Yoon","year":"2011","unstructured":"Yoon HW, Giraldo EA, Wijdicks EF. Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care. 2011;15(1):182\u20135.","journal-title":"Neurocrit Care"},{"issue":"4","key":"251_CR6","first-page":"489","volume":"71","author":"KA Lyseng-Williamson","year":"2011","unstructured":"Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011;71(4):489\u2013514.","journal-title":"Drugs"},{"issue":"11","key":"251_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707\u201324.","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"251_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0920-1211(01)00293-5","volume":"47","author":"I Ragueneau-Majlessi","year":"2001","unstructured":"Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47(1\u20132):55\u201363.","journal-title":"Epilepsy Res"},{"issue":"9990","key":"251_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(15)60243-4","volume":"386","author":"JL Mega","year":"2015","unstructured":"Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386(9990):281\u201391.","journal-title":"Lancet"},{"issue":"3","key":"251_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11920-010-0120-z","volume":"12","author":"M Bachawati","year":"2010","unstructured":"Bachawati M. Anticoagulation and psychotropic medications. Curr Psychiatry Rep. 2010;12(3):265\u201371.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"251_CR11","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","volume":"107","author":"J Hirsh","year":"2003","unstructured":"Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart A, American College of Cardiology F. American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692\u2013711.","journal-title":"Circulation"},{"issue":"1","key":"251_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","volume":"73","author":"LS Kaminsky","year":"1997","unstructured":"Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67\u201374.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"251_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/clpt.1992.39","volume":"51","author":"LD Heimark","year":"1992","unstructured":"Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51(4):398\u2013407.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"251_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-199410050-00003","volume":"10","author":"MD Freedman","year":"1994","unstructured":"Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994;10(5):381\u201394.","journal-title":"Drug Saf"},{"issue":"5","key":"251_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32(5):554\u201363.","journal-title":"Ann Pharmacother"},{"issue":"1\u20132","key":"251_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","volume":"53","author":"JC Cloyd","year":"2003","unstructured":"Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53(1\u20132):19\u201327.","journal-title":"Epilepsy Res"},{"issue":"10","key":"251_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/j.1875-9114.2012.01119","volume":"32","author":"A Nadkarni","year":"2012","unstructured":"Nadkarni A, Oldham MA, Howard M, Berenbaum I. Drug-drug interactions between warfarin and psychotropics: updated review of the literature. Pharmacotherapy. 2012;32(10):932\u201342.","journal-title":"Pharmacotherapy"},{"key":"251_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1749-6632.1971.tb46901.x","volume":"179","author":"EM Sellers","year":"1971","unstructured":"Sellers EM, Koch-Weser J. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci. 1971;179:213\u201325.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"251_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2125.1994.tb04251.x","volume":"37","author":"PE Rolan","year":"1994","unstructured":"Rolan PE. Plasma protein binding displacement interactions\u2014why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37(2):125\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"251_CR20","doi-asserted-by":"publisher","first-page":"h246","DOI":"10.1136\/bmj.h246","volume":"350","author":"M Jun","year":"2015","unstructured":"Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015;350:h246.","journal-title":"BMJ"},{"issue":"4","key":"251_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1378\/chest.15-1719","volume":"149","author":"K Dahal","year":"2016","unstructured":"Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016;149(4):951\u20139.","journal-title":"Chest"},{"issue":"7","key":"251_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"6","key":"251_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/MNH.0b013e3283136732","volume":"17","author":"TD Nolin","year":"2008","unstructured":"Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens. 2008;17(6):555\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8","key":"251_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","volume":"4","author":"AW Dreisbach","year":"2008","unstructured":"Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065\u201374.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"251_CR25","first-page":"75","volume":"25","author":"D Ganeval","year":"1986","unstructured":"Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, et al. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol. 1986;25(2):75\u201380.","journal-title":"Clin Nephrol"},{"issue":"7","key":"251_CR26","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.clinthera.2009.07.015","volume":"31","author":"AH Abdelhafiz","year":"2009","unstructured":"Abdelhafiz AH, Myint MP, Tayek JA, Wheeldon NM. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther. 2009;31(7):1534\u20139.","journal-title":"Clin Ther"},{"issue":"5","key":"251_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","volume":"56","author":"NA Limdi","year":"2010","unstructured":"Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56(5):823\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"251_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/FTD.0000000000000405","volume":"39","author":"E Wallenburg","year":"2017","unstructured":"Wallenburg E, Klok B, de Jong K, de Maat M, van Erp N, Stalpers-Konijnenburg S, et al. Monitoring protein-unbound Valproic acid serum concentrations in clinical practice. Ther Drug Monit. 2017;39(3):269\u201372.","journal-title":"Ther Drug Monit"},{"key":"251_CR29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526\u201348.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"251_CR30","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/epi.13802","volume":"58","author":"PN Patsalos","year":"2017","unstructured":"Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58(7):1234\u201343.","journal-title":"Epilepsia"},{"issue":"1","key":"251_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13054-018-2066-1","volume":"22","author":"S Farrokh","year":"2018","unstructured":"Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA. Antiepileptic drugs in critically ill patients. Crit Care. 2018;22(1):153.","journal-title":"Crit Care"},{"issue":"4","key":"251_CR32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","volume":"18","author":"CJ Landmark","year":"2016","unstructured":"Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Dis. 2016;18(4):367\u201383.","journal-title":"Epileptic Dis"},{"issue":"7","key":"251_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239\u201376.","journal-title":"Epilepsia"},{"key":"251_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.yebeh.2014.09.069","volume":"42","author":"D Stepanova","year":"2015","unstructured":"Stepanova D, Beran RG. The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy Behav. 2015;42:7\u20139.","journal-title":"Epilepsy Behav"},{"key":"251_CR35","doi-asserted-by":"crossref","unstructured":"Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014;(9):Cd003723.","DOI":"10.1002\/14651858.CD003723.pub3"},{"key":"251_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","volume":"114","author":"RC Mundlamuri","year":"2015","unstructured":"Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam\u2014pilot study. Epilepsy Res. 2015;114:52\u20138.","journal-title":"Epilepsy Res"},{"issue":"4","key":"251_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2710.2007.00831.x","volume":"32","author":"S Dutta","year":"2007","unstructured":"Dutta S, Faught E, Limdi NA. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Ther. 2007;32(4):365\u201371.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"251_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40263-014-0167-1","volume":"28","author":"E Trinka","year":"2014","unstructured":"Trinka E, Hofler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs. 2014;28(7):623\u201339.","journal-title":"CNS Drugs"},{"issue":"3","key":"251_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.braindev.2010.04.003","volume":"33","author":"A Visudtibhan","year":"2011","unstructured":"Visudtibhan A, Bhudhisawadi K, Vaewpanich J, Chulavatnatol S, Kaojareon S. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. Brain Dev. 2011;33(3):189\u201394.","journal-title":"Brain Dev"},{"issue":"3","key":"251_CR40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","volume":"49","author":"W Nasreddine","year":"2008","unstructured":"Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438\u201345.","journal-title":"Epilepsia"},{"issue":"12","key":"251_CR41","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/j.1468-1331.2011.03420.x","volume":"18","author":"WB Chen","year":"2011","unstructured":"Chen WB, Gao R, Su YY, Zhao JW, Zhang YZ, Wang L, et al. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011;18(12):1391\u20136.","journal-title":"Eur J Neurol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0251-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T18:40:19Z","timestamp":1605120019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0251-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0251-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]},"assertion":[{"value":"4 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethical review committee of Shenyang First People\u2019s Hospital, Shenyang Brain Institute, Shenyang Medical College Affiliated Shenyang Brain Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to publish all the personal and medical details included in the case report, as well as the accompanying laboratory data was obtained by the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"60"}}